Atazanavir/ritonavir - Mylan Laboratories

Drug Profile

Atazanavir/ritonavir - Mylan Laboratories

Alternative Names: Anzavir-R; Ritonavir/atazanavir

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mylan Laboratories Limited
  • Class Antiretrovirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 21 Mar 2017 Mylan's Atazanavir/ritonavir is still tentatively approved for HIV infections in USA (PO)
  • 30 Jun 2012 Launched for HIV infections in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top